HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Big opportunities for small molecules in immuno-oncology

(2015) Jerry L. Adams et al.   NATURE REVIEWS DRUG DISCOVERY

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

(2013) A. C. West et al.   CANCER RESEARCH

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance

(2013) Emily L. Hopewell et al.   JOURNAL OF CLINICAL INVESTIGATION

Synergistic Expression of the CXCL10 Gene in Response to IL-1  and IFN-  Involves NF- B, Phosphorylation of STAT1 at Tyr701, and Acetylation of Histones H3 and H4

(2013) S. J. Burke et al.   JOURNAL OF IMMUNOLOGY

Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

(2013) T. Ma et al.   MOLECULAR CANCER THERAPEUTICS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

(2009) D. D. Vo et al.   CANCER RESEARCH